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Abstract: Current recommendations to consider initiation of palliative care (PC) in COPD patients 
are often based on an expected poor prognosis. However, this approach is not evidence-based, 
and which and when COPD patients should start PC is controversial. We aimed to assess whether 
current suggested recommendations for initiating PC were sufficiently reliable. We identified 
prognostic variables proposed in the literature for initiating PC; then, we ascertained their rela-
tionship with 1-year mortality, and finally, we validated their utility in our cohort of 697 patients 
hospitalized for COPD exacerbation. From 24 articles of 499 screened, we selected 20 variables 
and retrieved 48 original articles in which we were able to calculate the relationship between 
each of them and 1-year mortality. The number of studies where 1-year mortality was detailed for 
these variables ranged from 9 for previous hospitalizations or FEV
1
 #30% to none for albumin 
#25 mg/dL. The percentage of 1-year mortality in the literature for these variables ranged from 
5% to 60%. In the validation cohort study, the prevalence of these proposed variables ranged from 
8% to 64%; only 10 of the 18 variables analyzed in our cohort reached statistical significance 
with Cox regression analysis, and none overcame an area under the curve $0.7. We conclude 
that none of the suggested criteria for initiating PC based on an expected poor vital prognosis in 
COPD patients in the short or medium term offers sufficient reliability, and consequently, they 
should be avoided as exclusive criteria for considering PC or at least critically appraised.
Keywords: COPD, palliative care, prognosis, mortality, survival, end of life
Introduction
COPD is the third leading cause of death worldwide and the seventh in the combination 
of years of life lost or lived with disability.1 Several studies have shown that patients 
with severe COPD have a similar or greater number of symptoms than those of patients 
with inoperable lung cancer.2 Nonetheless, COPD patients are less likely to receive 
palliative care (PC) compared with cancer patients.3
PC is not limited to the terminal phase of the disease and can be delivered alongside 
standard therapies, according to the needs and preferences of patients and regardless 
of the risk of death in the short or medium term.4 Traditionally, PC has mainly been 
used for patients with neoplastic diseases, where it has improved symptoms, quality 
of life and even survival, but its implementation has also proved effective in several 
chronic noncancer diseases, including COPD.5
One of the main barriers for initiating PC in COPD is the unpredictability of vital 
prognosis in an individual patient. Many COPD patients present a gradual deteriora-
tion, others stability for years, while a subgroup suffers acute COPD exacerbations. 
Usually, COPD patients are very resilient and survive several of these episodes 
during their lives, including some severe exacerbations – defined as those requiring 
hospitalization or even ventilator support – until the patient’s death. This uncertain 
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prognosis complicates matters for clinicians unfamiliar with 
PC in initiating discussions about PC and end-of-life care 
planning.6 Although many variables have demonstrated a 
close relationship with impaired survival in COPD, their 
utility for evaluating survival in an individual patient in the 
short or medium term is debatable, and therefore, their useful-
ness as main criteria to initiate PC is not well established.
The main objective of our study was to assess whether 
current suggested recommendations for PC based on an 
expected 1-year mortality are sufficiently reliable.
Methods
This study was structured in 3 phases. 1) To identify variables 
proposed in the literature as main criteria for considering 
initiating PC in COPD patients, based on a foreseeable poor 
prognosis in the short or medium term (#1-year survival). 
2) To ascertain the relationship between these proposed 
variables and 1-year mortality, retrieving the data from the 
original studies. 3) We sought to validate the utility of the pro-
posed variables in a cohort of patients hospitalized for COPD 
exacerbation. We followed the PRISMA (preferred reporting 
items for systematic reviews and meta-analyses) guidance for 
the systematic review and the TRIPOD (transparent reporting 
of a multivariable prediction model for individual prognosis 
or diagnosis) guidance for the validation study.
For this purpose, we conducted a comprehensive search 
in MEDLINE, using the search strategy detailed in the 
Supplementary materials. We retrieved and evaluated all 
publications, including systematic reviews, reviews or 
expert opinion papers that included variables considered 
as poor prognostic factors, defined as a projected median 
survival #1 year, as principal criteria for initiating PC. COPD 
guidelines were also reviewed, selecting those that included 
recommendations for considering PC based on prognostic 
variables associated with high probability of death in the 
coming months. PC guidelines for non-oncological diseases, 
in which the purpose for initiating PC was based on similar 
criteria, were added. We also searched the reference lists of 
identified articles for further relevant papers.
From these reviewed articles, we selected those variables 
and their respective most often referenced cutoffs as sug-
gested criteria for initiating PC based on a foreseeable poor 
prognosis in the short or medium term (,1 year). Addition-
ally, we considered 3 multicomponent prognosis indexes 
(Body mass index, Obstruction, Dyspnea and 6 minutes walk-
ing test [BODE], Body mass index, Obstruction, Dyspnea 
and severe exacerbations [BODEX], and Comorbidity, 
Obstruction, Dyspnea and severe exacerbations [CODEX]) 
deemed to be of special interest.
Subsequently, we retrieved all available original articles 
from which the selection of variables was drawn, and then a 
new search was performed focussing specifically on each of 
these individual variables and their relationship with 1-year 
mortality. Information on 1-year mortality in these articles 
was extracted when detailed in the text or alternatively if they 
could be estimated from survival curve figures embedded in 
the articles (Supplementary materials).
Finally, the reliability of selected variables was validated 
in a database based on pooled-individual analysis data from 
697 patients discharged after a hospitalization for acute 
exacerbation of COPD and with complete 1-year follow-up 
for mortality, based on 4 previously published cohorts 
(Supplementary materials).7–11 In order to not duplicate data, 
these articles were expressly excluded from the previous 
search. BODE, BODEX and CODEX multicomponent 
indexes were calculated with the cutoffs previously described 
in the original studies.12–14 (Table S1).
In this database, we specifically analyzed each of 
the variables suggested in the reviewed articles with the 
percentages of the population that met each of these fac-
tors and their relationship with mortality in the year after 
hospital discharge, using the cutoffs previously proposed 
in the literature.
All participants gave their written informed consent to 
participate, and the ethics committee of Universitari Hospital 
Mutua de Terrassa approved all previous studies.
statistical analysis
Parametric data were expressed as mean and standard devia-
tion (SD) and analyzed with analysis of variance (ANOVA) 
or Mann–Whitney U test according to the distribution of the 
variables. Qualitative data were expressed as numbers and 
percentages and analyzed with the chi-square test. We also 
calculated the hazard ratio and 95% confidence intervals for 
survival time using a Cox logistic regression analysis and 
Kaplan–Meier survival curves, and statistical significance 
was calculated with the log-rank test. Receiver operating 
characteristic (ROC) curves and their area under the curve 
(AUC) for 1-year mortality were also analyzed separately 
for qualitative and quantitative variables calculating their 
sensitivity, specificity and Youden’s J Statistic (J = sensivity + 
specificity -1). The comparison of AUC was performed with 
the DeLong method. Statistical significance was established 
at P,0.05.
Results
For the variables associated with poor prognosis described 
in the literature as main criteria for initiating PC in COPD 
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patients, we retrieved 499 articles. Of these, in 15 articles – 4 
systematic reviews and 11 revision articles – several variables 
considered as useful factors to initiate PC based on a 
foreseeable 1-year mortality were selected for subsequent 
analysis.6,15–31 Additionally, a total of 28 COPD clinical 
practice guidelines were reviewed. Of these, 7 recommended 
various prognostic factors as criteria for starting PC. Another 
2 guides of non-oncological PC, based on a similar approach, 
were also reviewed (Supplementary materials). Altogether, 
a total of 24 articles were selected, from which 20 variables 
considered in the bibliography as useful predictors of poor 
prognosis for considering PC were extracted and analyzed 
(Figure 1). All revised COPD guidelines and their references 
are detailed in Table S2.
After searching for previously published original articles 
on these 20 selected variables and their association with 
1-year mortality, we retrieved 48 original articles in which we 
were able to calculate the relationship between each of them 
and the percentage of 1-year mortality. These 20 selected 
variables, their percentages of 1-year mortality in original 
articles and number of references, are detailed in Table 1. 
References of original articles are shown in Table S3.
In Figure 2, the number of studies reviewed for each 
variable and their mean percentages of 1-year mortality are 
detailed. As shown in Table 1 and Figure 2, the percentage 
of 1-year mortality for the proposed variables varies widely 
between different original articles, reflecting the diverse base-
line characteristics of the populations studied. Similarly, the 
number of original studies with which we were able to calculate 
1-year mortality ranged from 9 for hospital admissions in 
the previous year or FEV
1
 (%) to a single study for being 
married and none for variables such as a plasma albumin 
level ,25 mg/dL, a criterion proposed by Salpeter et al.16
In our validation cohort study, 697 patients hospitalized 
for COPD exacerbation were included. The mean age of 
Figure 1 Flowchart diagram of systematic review.
Abbreviation: PC, palliative care.
Table 1 Variables related with 1-year mortality in the systematic 
review
Variables N H.M. (%) L.M. (%) Mean (SD)
epidemiological
age $70 years 3 51 10 27 (21.4)
Unmarried 1 5 5
Physical dependence 1 60 60
Poor quality of life 6 27 5 16.7 (7.1)
systemic variables
BMI #21 kg/m2 4 56 15 32.3 (19.4)
serum albumin ,25 mg/dl 0
Comorbidities 2 40 8 24 (22.6)
Depression 4 25 10 19.8 (6.7)
anemia 1 40 40
Cor pulmonale/Ph 3 30 8 15.7 (12.4)
respiratory variables
Previous hospitalization 9 42 5 23.4 (12)
FeV1 #30% 9 24 4 12.6 (5.9)
Dyspnea (mMrC scale) 2 15 14 14.5 (0.7)
hypoxemia 4 35 20 25.3 (6.7)
hypercapnia 3 30 12 20.6 (7.4)
Invasive ventilation 4 54 43 47.5 (4.7)
nIV 4 48 22 35.8 (11)
Multicomponent index
BODe 5 20 10 13.8 (4.8)
Notes: n, number of studies retrieved; h.M., higher percentage of 1-year mortality 
in retrieved articles; l.M., lower percentage of 1-year mortality in retrieved articles; 
Mean (sD), mean and standard deviation of 1-year mortality in retrieved articles.
Abbreviations: Ph, pulmonary hypertension; BMI, body mass index; mMrC, 
modified dyspnea Medical Research Council; NIV, noninvasive ventilation; BODE, 
Body mass index, Obstruction, Dyspnea and 6 minutes walking test.





the study population was 72.5 years (SD=9.5), with 93% 
males and an overall 17.5% 1-year mortality. The main 
characteristics of the study population and their relation 
with mortality are shown in Table 2. On average, deceased 
patients were significantly older and had greater functional 
impairment, more comorbidities, higher levels of depres-
sion or dyspnea and more previous admissions for COPD 
exacerbation (all P,0.01). Similarly, the scores obtained in 
Figure 2 systematic review, number of studies and 1-year mortality.
Notes: The number of circles in each variable represents the number of articles retrieved and their position with respect to Y axis, the mean average mortality. 
Abbreviations: exacer, severe exacerbations of COPD in the previous year; Comor, comorbidity; Depres, depression; Qol, quality of life; BMI, body mass index; CP, cor 
pulmonale; IV, invasive ventilation; nIV, noninvasive ventilation; BODe, Body mass index, Obstruction, Dyspnea and 6 minutes walking test.
Table 2 Characteristics of the cohort study population and 1-year mortality
Variables Alive (575) Dead (122) Total (697) P-value
age, years (sD) 71.8 (9.4) 75.8 (9.3) 72.5 (9.5) 0.001
Male (%) 539 (94%) 111 (91%) 650 (93%) 0.32
smoking (pack-years) (sD) 57.2 (28.5) 61.7 (34.4) 57.9 (29.5) 0.23
Physical dependence (Katz) (sD) 5.4 (1.1) 5.1 (1.2) 5.4 (1.2) 0.008
Quality of life (sgrQ) (sD) 50.5 (16) 56.9 (19.4) 51.5 (16.8) 0.02
Body mass index (sD) 27.3 (4.9) 25.9 (4.9) 27 (4.9) 0.006
albumin, mg/dl (sD) 40.6 (4.9) 39.9 (4.6) 40.5 (4.9) 0.33
Comorbidities (Charlson) (sD) 2.5 (1.6) 3 (2) 2.6 (1.7) 0.004
Depression (Yesavage) (sD) 4.5 (3.4) 6.2 (3.8) 4.8 (3.5) 0.001
Cor pulmonale (%) 170 (30%) 43 (35%) 213 (31%) 0.23
hospital admissions in the previous year (sD) 1.4 (1.7) 1.7 (2) 1.4 (1.7) 0.047
FeV1 % post-PBD (sD) 43.1 (15.2) 42 (14.9) 42.9 (15.2) 0.49
FVC % post-PBD (sD) 67 (18.6) 64.2 (18.1) 66.5 (18.5) 0.14
FeV1/FVC (sD) 49.4 (11.2) 49 (12.3) 49.4 (11.4) 0.67
Dyspnea (mMrC scale) (sD) 2.3 (1.2) 2.7 (1.5) 2.4 (1.2) 0.001
pO2 (sD) 61.7 (17.3) 60.9 (18.5) 61.6 (17.5) 0.65
pCO2 (sD) 45 (13) 45.5 (15.4) 45 (13.4) 0.7
Chronic oxygen therapy (%) 159 (27.7%) 47 (38.5%) 206 (29.6%) 0.02
BODe (sD) 4.6 (2) 5.8 (2.6) 4.7 (2.1) 0.02
BODeX (sD) 4.4 (2.3) 5.2 (2.6) 4.5 (2.3) 0.001
CODeX (sD) 5 (2.2) 6.3 (2) 5.2 (2.2) 0.001
Note: analysis was performed with anOVa, Mann–Whitney U test or chi-square test according to the properties of the variables.
Abbreviations: SD, standard deviation; SGRQ, Saint George’s Respiratory Questionnaire; mMRC, modified dyspnea Medical Research Council; ANOVA, analysis of 
variance; BODe, Body mass index, Obstruction, Dyspnea and 6 minutes walking test; BODeX, Body mass index, Obstruction, Dyspnea and severe exacerbations; CODeX, 
Comorbidity, Obstruction, Dyspnea and severe exacerbations; FVC, forced vital capacity; PBD, postbronchodilatation.
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the BODE, BODEX and CODEX indices were consistently 
higher for deceased patients (Table 2). The cause of death 
was respiratory in 51.6% of cases, cardiovascular in 7.4%, 
cancer in 6.6%, others in 2.5% and unknown in 32% of 
patients, respectively.
In Table 3, we applied in our cohort for each one of these 
variables – excluding history of invasive or noninvasive 
mechanical ventilation and presence of anemia due to lack 
of data – dichotomized at the commonly proposed cutoffs, 
alongside with the percentage of population meeting the 
suggested criteria, the percentage of related 1-year mortality, 
their sensitivity, specificity and Youden’s index. In this 
table, the statistical significance, hazard ratios, and 95% 
confidence intervals were calculated with Cox logistic 
regression analysis. As detailed in the table, the prevalence 
of selected variables in our population varied largely. More 
than half of patients were aged 70 years, with scores sug-
gestive of depression in the Yesavage scale ($5 points), 
and had at least 1 hospitalization during the previous year 
or dyspnea levels of 3 or 4 on the modified dyspnea Medi-
cal Research Council (mMRC) scale. In contrast, severe 
physical dependence (loss of 3 or more activities of daily 
living), lower body mass index (BMI; #21 kg/m2) or serum 
albumin ,35 mg/dL were present in ,10% of patients. 
Furthermore, the percentage of mortality for the selected 
variables ranged between 20% and 30%, and perhaps, 70% 
of patients who met a single poor prognostic criterion were 
alive at 1 year (Figure 3).
Although 10 of the 18 variables analyzed in our cohort 
reached statistical significance for 1-year mortality, only 
age $70 years, depression (Yesavage scale $5 points), 
health-related quality of life (Saint George’s Respiratory 
Questionnaire $60 points) and dyspnea 3–4 in the mMRC 
scale had a concomitant sensibility and specificity $50%. 
Age $70 years had the greatest sensitivity (0.71) with a 
specificity of 0.41; in contrast, the greatest specificity in our 
cohort was associated with severe functional dependence 
(0.92) but at the expense of a very low sensitivity (0.11).
In Table 4, the AUC for quantitative variables expressed 
as continuous (non-tailed) is detailed. The best AUC was 
obtained by the CODEX index (0.68) and their combina-
tion with the Yesavage depression scale (0.69), although 
without statistical significance versus CODEX alone (P=0.8) 
(Figure 4). Other variables were not included in this model, 
since the CODEX index already includes age, comorbidity 
measured by the Charlson index, FEV
1
 (%), dyspnea and 
hospitalizations in the previous year.
Finally, and given that the models proposed in the 
literature as main criteria for considering PC based on 
an expected poor prognosis are usually composed of a 
combination of variables, we tested an adaptation of the 
criteria proposed by Curtis et al.15 A total of 86% of patients 
had 2 or more of these criteria – the cutoff recommended 
by the author – but the 1-year mortality differences among 
patients who met $2 criteria and the rest did not reach 
statistical significance (P=0.83). If we use a score $3, 
Table 3 Predictive mortality variables in the cohort study
Variables % 1-year mortality (%) Sen Spe Y P-value HR 95% CI
age $70 years 64 20 0.74 41.6 0.16 0.001 2 1.3–3
Unmarried 23 25 0.42 0.60 0.02 0.29 n.c. 0.5–1.5
Physical dependence (loss $3 activities of daily living) 8 22 0.11 0.92 0.02 0.31 1.36 0.75–2.48
Poor quality of life (sgrQ $61) 33 28 0.53 0.71 0.24 0.001 2.6 1.44–4.66
BMI #21 kg/m2 10 27 0.17 0.91 0.07 0.02 1.81 1.1–3
albumin #35 mg/dl 10 33 0.19 0.92 0.11 0.03 2.2 1.6–4.5
Comorbidities (Charlson $3) 23 22 0.28 0.78 0.07 0.07 1.4 0.97–2.14
Depression (Yesavage $5 points) 57 27 0.61 0.61 0.21 0.003 2.24 1.32–3.8
Cor pulmonale 31 21 0.35 0.7 0.05 0.28 1.2 0.85–1.8
$1 hospitalization in the previous year 63 18 0.68 0.47 0.15 0.24 1.27 0.87–1.84
Chronic oxygen therapy 30 22 0.39 0.72 0.11 0.01 1.6 1.1–2.3
FeV1 #30% 22 19 0.25 0.78 0.3 0.5 1.12 0.74–1.69
Dyspnea (mMrC scale $3) 55 24 0.59 0.57 0.16 0.002 1.8 1.25–2.61
pO2 #50 mmhg 21 21 0.28 0.77 0.06 0.1 1.33 0.88–2.1
pCO2 $50 mmhg 26 21 0.31 0.75 0.06 0.2 1.3 0.87–1.94
BODe $7 21 24 0.47 0.82 0.29 0.007 3.74 1.4–9.7
BODeX $7 18 24 0.21 0.84 0.05 0.07 1.49 0.97–2.3
CODeX $7 21 29 0.49 0.73 0.22 0.001 2.42 1.7–3.5
Notes: %, percentage of the population with the variable criteria. Statistical significance, HRs, and 95% CIs were calculated with Cox logistic regression analysis.
Abbreviations: HR, hazard ratio; CI, confidence interval; SGRQ, Saint George’s Respiratory Questionnaire; BMI, body mass index; mMRC, modified dyspnea Medical 
Research Council; Sen, sensitivity; Spe, specificity; Y, Youden’s index; n.c., non calculated; BODE, Body mass index, Obstruction, Dyspnea and 6 minutes walking test; 
BODeX, Body mass index, Obstruction, Dyspnea and severe exacerbations; CODeX, Comorbidity, Obstruction, Dyspnea and severe exacerbations.





Table 4 aUC for selected variables in the cohort study
Variables AUC P-value 95% CI
age, years 0.62 0.0001 0.58–0.65
Physical dependence (Katz index) 0.59 0.0005 0.55–0.62
Quality of life (sgrQ) 0.52 0.01 0.48–0.55
BMI 0.59 0.001 0.55–0.63
albumin 0.5 0.9 0.46–0.54
Comorbidities (Charlson index) 0.56 0.02 0.52–0.6
Depression (Yesavage scale) 0.63 0.001 0.57–0.68
FeV1 0.52 0.5 0.48–0.55
Dyspnea 0.58 0.002 0.55–0.62
pO2, mmhg 0.52 0.52 0.48–0.57
pCO2, mmhg 0.52 0.58 0.48–0.55
BODe 0.54 0.05 0.49–0.57
BODeX 0.59 0.001 0.55–0.63
CODeX 0.68 0.0001 0.62–0.72
Curtis criteria 0.64 0.0001 0.6–0.68
Abbreviations: AUC, area under the curve; CI, confidence interval; SGRQ, Saint 
george’s respiratory Questionnaire; BMI, body mass index; BODe, Body mass 
index, Obstruction, Dyspnea and 6 minutes walking test; BODeX, Body mass 
index, Obstruction, Dyspnea and severe exacerbations; CODeX, Comorbidity, 
Obstruction, Dyspnea and severe exacerbations.
Figure 3 Kaplan–Meier curves for (A) age, (B) depression, (C) dyspnea, and (D) CODeX index.
Abbreviations: mMRC, modified dyspnea Medical Research Council; CODEX, Comorbidity, Obstruction, Dyspnea and severe exacerbations.
61% of patients met the criteria, with statistical significance 
(P,0.0001; HR: 2.49; 95% CI: 1.68–3.7) and an AUC 
of 0.64 (0.6–0.68). In contrast, the criteria suggested by 
Salpeter are so restrictive that none of the patients in our 
cohort fulfilled the proposed criteria, even after changing 
the cutoffs of albumin from 25 to 35 mg/dL and BMI from 
18 to 21 kg/m2.16
Discussion
The main conclusion of our study is that none of the sug-
gested criteria for initiating PC based on an expected poor 
vital prognosis in COPD patients in the short or medium 
term offers sufficient reliability, and perhaps, they should be 
avoided as exclusive criteria for considering PC or at least 
critically evaluated.
Obviously, this does not mean that these proposed 
variables and multicomponent indices are not useful 
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predictors of survival in COPD, but as we show in our study, 
their applicability to individual patients at short or medium 
term is limited. This is because these prognostic factors are 
usually related with long-term survival (3–10 years) and their 
utility has been explored in diverse populations, and they are 
difficult to apply in any particular patient. For example, the 
most widely used criterion for evaluating COPD severity is 
the postbronchodilator FEV
1
 (%), which is clearly related 
with survival. This was again confirmed in a recent study 
(COCOMICS) performed in a large pooled analysis of COPD 
patients. In this study, patients with an FEV
1
 (%) ,35% 
had a 6-fold greater 5-year mortality than the group with an 
FEV
1
 $75%. However, the probability of survival for patients 
with FEV
1
 (%) #35% was 46% at 5 years.32 Moreover, in this 
study, FEV
1
 (%) was a better predictor of survival than dys-
pnea measured with the mMRC scale, contrary to Nishimura 
et al33 and even to this cohort. The most plausible explanation 
is the broad spectrum of patients included in the COCOMICS 
study, while in the Nishimura et al’s study and in this cohort, 
patients included had more severe COPD, suggesting that in 




Furthermore, these criteria vary widely according to the 
population studied. For example, a BODE score from 7 to 10, 
proposed as a criterion for considering PC in COPD patients 
in several publications, carries a year mortality ranging from 
7% in the original cohort, based on ambulatory patients 
without comorbidity, to 20% in patients hospitalized for 
COPD exacerbation.10,34 Of note, the highest percentages 
of mortality for age or BMI in the literature review were 
obtained from the study of Connors et al.35 This study is part 
of the SUPPORT project – conducted in patients with a life 
expectancy of ,6 months for several chronic diseases – and in 
it COPD includes only patients hospitalized with hypercapnic 
respiratory failure and without spirometric confirmation.36
Another of the proposed approaches for considering PC in 
chronic illness, and not analyzed in our cohort due to lack of 
data, is the so-called surprise question: “Would I be surprised 
if my patient were to die in the next 12 months?” However, 
its application in COPD has proven highly imprecise. Thus, 
in the SUPPORT study, the interviews were performed with 
physicians 5 days before the deaths of COPD patients, and the 
doctors predicted an expected survival probability of 50% at 
6 months.37 By contrast, in patients hospitalized in intensive 
care units (ICUs) for COPD or asthma, physicians estimated 
that only 10% of patients would survive 6 months, com-
pared with the 40% observed during follow-up.38
Similarly, a criterion widely suggested as a useful predic-
tor of short- or medium-term mortality in chronic diseases 
is the progressive physical functional dependence. Several 
authors believe that in patients with severe COPD, the last 
year of life is characterized by a gradual dependence in 
daily living activities that worsens with each exacerbation. 
Although it is well known that severe COPD exacerbations 
cause a decrease of physical activity, in most of the decedents 
for chronic diseases, the course of disability in the last year 
of life did not follow a predictable pattern, and individual 
trajectories are highly variable.39
In our opinion, reinforced by the data of this study, 
the decision to start PC – together with restorative care – 
should be based on the presence of symptoms refractory to 
conventional therapy, alongside the preferences of patients. 
PC includes, among other elements, care planning com-
munication, end-of-life decisions, limitation of aggressive 
treatments (ICU admission, mechanical ventilation and 
cardiopulmonary resuscitation) and symptomatic treatment, 
while always considering the physical, psychosocial and spiri-
tual aspects and preferences of patients.40 Regrettably, PC is 
often erroneously considered restricted to terminal care, when 
it has been shown to be applicable and of value in other stages 
of COPD.41 It does not imply abandoning other therapies, 
and as shown in our article, it is not limited by the prognostic 
uncertainty inherent to COPD. Several studies have shown 
that mortality in COPD is highly concentrated in the days or 
weeks following an exacerbation and frequently related with 
comorbidities, and therefore hardly predictable.11,42
Figure 4 rOC curves.
Notes: Black line, CODeX + Yesavage; blue line, CODeX; orange line, Yesavage; 
red line, Curtis criteria; violet line, dyspnea.
Abbreviations: rOC, receiver operating characteristic; CODeX, Comorbidity, 
Obstruction, Dyspnea and severe exacerbations.





Our study highlights the importance of symptoms such as 
dyspnea and depression in patients hospitalized for COPD, 
not only for their high prevalence and prognostic implica-
tions but also for their impact on the quality of life of these 
patients. These symptoms can be improved by PC alongside 
the usual medical therapies, non-pharmacological measures 
and psychological treatment.
Our study has some limitations. First, in the search of 
original articles, only publications in which we were able to 
extract the percentage of 1-year mortality were included. That 
is, if a study examined the relationship between a prognostic 
variable and 3-year survival, but 1-year mortality was not 
detailed in the text or readily calculated from the survival 
curves, it was not included. Second, the analyzed cohorts 
included only patients hospitalized for COPD exacerba-
tion, among whom mortality is generally higher than that in 
ambulatory patients. However, we believe that our findings 
are applicable to outpatients with severe COPD with a his-
tory of previous admissions. Finally, like other COPD stud-
ies performed in Spain, the percentage of females included 
in our study is small, and we were unable to explore the 
gender differences.
In conclusion our study demonstrates that none of the 
suggested criteria for initiating PC in COPD patients based 
on an expected poor vital prognosis in the short or medium 
term offers sufficient reliability, and perhaps, the initia-
tion of PC in COPD patients should not be based on life 
expectancy, since this is extremely imprecise for any given 
individual patient.
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